GALVUS NOVARTIS PDF

Novartis’ Galvus (vildagliptin) is a member of a new class of oral antidiabetic agents known as dipeptidyl peptidase IV inhibitors (DPP-IV) inhibitors or ‘incretin . Galvus Approval Status. FDA Approved: No Brand name: Galvus Generic name: vildagliptin. Previous Name: LAF Company: Novartis Pharmaceuticals. Vildagliptin is an oral anti-hyperglycemic agent (anti-diabetic drug) of the dipeptidyl The European Medicines Agency has also approved a combination of vildagliptin and metformin, vildagliptin/metformin (Eucreas by Novartis) as an oral.

Author: Gushicage Toran
Country: Puerto Rico
Language: English (Spanish)
Genre: Relationship
Published (Last): 3 April 2008
Pages: 444
PDF File Size: 16.44 Mb
ePub File Size: 3.28 Mb
ISBN: 269-9-80820-631-5
Downloads: 51802
Price: Free* [*Free Regsitration Required]
Uploader: Sara

Otilonium The risk or severity of hypoglycemia can be increased when Otilonium is combined with Vildagliptin. The therapeutic efficacy of Vildagliptin can be increased when used in combination with Prulifloxacin.

Rare cases of hepatic dysfunction including hepatitis have been reported. The therapeutic efficacy of Vildagliptin can be increased when used in noovartis with Enoxacin. Initial marketing-authorisation documents List item. You will be re-directed back to this page where you will have the ability to comment. The risk or severity of hypoglycemia can be increased when Isradipine is combined with Vildagliptin. This information is intended for use by health professionals.

Galvus 50 mg Tablets

Leuprolide The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Leuprolide. Phenyl aminosalicylate Phenyl aminosalicylate may increase the hypoglycemic activities of Vildagliptin. By increasing endogenous GLP-1 levels, vildagliptin also enhances the sensitivity of alpha cells to glucose, resulting in more glucose-appropriate glucagon secretion. Dosulepin Dosulepin may decrease the hypoglycemic activities of Vildagliptin.

  MANIFIESTO ECOSOCIALISTA INTERNACIONAL PDF

Phenelzine Phenelzine may increase the hypoglycemic activities of Vildagliptin. Administration of vildagliptin enhances GLP-1’s ability to produce insulin in response to elevated concentrations of blood glucose, inhibit the release of glucagon following meals, slow the rate of nutrient absorption into the bloodstream, slow the rate of gastric emptying, and reduce food novarttis.

The risk or severity of angioedema can be increased when Vildagliptin is combined with Sacubitril. Latest Celebrating a year of career highlights 12 DEC The risk or severity of hypoglycemia can be increased when Nimesulide is combined with Vildagliptin.

The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Vildagliptin. Everolimus The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Everolimus. The risk or severity of hypoglycemia can be increased when Vildagliptin is combined with Insulin Beef. The risk or severity of hypoglycemia can be increased when Dexniguldipine is combined with Vildagliptin. Publication details Marketing-authorisation holder Novartis Europharm Limited.

The risk or severity of hypoglycemia can be increased when Dotarizine is combined with Vildagliptin. The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Progesterone.

Galvus (vildagliptin) FDA Approval Status –

The risk or severity of hypoglycemia can be increased when Vildagliptin is combined with Semaglutide. Sulfamethizole The therapeutic efficacy of Vildagliptin can be increased when used in combination with Sulfamethizole.

  CORAN KALOUN PDF

Galvus has received a licence for dual therapy in combination with:. Garenoxacin The therapeutic efficacy of Vildagliptin can be increased when used in combination with Garenoxacin. The risk or severity of hypoglycemia can be increased when Lacidipine is combined with Vildagliptin.

Clopamide The therapeutic efficacy of Noartis can be increased when used in combination with Clopamide. The therapeutic efficacy of Vildagliptin can be increased halvus used in combination with Nemonoxacin. Nelfinavir The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Nelfinavir.

Agmatine The risk or severity of hypoglycemia can be increased when Agmatine is combined with Vildagliptin. The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Prednylidene. Fluoxetine The risk or severity of hypoglycemia ggalvus be increased when Fluoxetine is combined with Vildagliptin.

Dabrafenib The therapeutic efficacy of Vildagliptin can be decreased when used balvus combination with Dabrafenib. The therapeutic efficacy of Vildagliptin can be increased when used in combination with Tosylchloramide.

Icandra (previously Vildagliptin / metformin hydrochloride Novartis) | European Medicines Agency

In other projects Wikimedia Commons. The therapeutic efficacy of Vildagliptin can be increased when used novwrtis combination with Trovafloxacin. Sumatriptan The therapeutic efficacy of Vildagliptin can be increased when used in combination with Sumatriptan.